TY - JOUR
T1 - Anticancer activity of 4-[1-oxo-(substituted aryl)-2-propenyl]-3- phenylsydnones
AU - Satyanarayana, K.
AU - Deshpande, S.R.
AU - Rao, B.S.
AU - Rao, M.N.A.
N1 - Cited By :10
Export Date: 10 November 2017
CODEN: IJSID
Correspondence Address: Satyanarayana, K.; Natco Research Center, Natco Pharma Ltd., B-13, Sanathnagar, Hyderabad-500 018, India; email: [email protected]
References: Kier, L.B., (1967) J. Pharm.Sci, 56, p. 149; Newton, C.G., Ramsden, C.A., (1982) Tetrahedron, 38, p. 2965; Satyanarayana, K., Rao, M.N.A., (1995) J. Pharm. Sci, 84, p. 263; Satyanarayana, K., Rao, M.N.A., (1995) Eur. J. Med. Chem, 30, p. 641; Satyanarayana, K., Ra, M.N.A., (1995) Indian J. Pharm. Sci, pp. 57-243; Anto, R.J., Kuttan, R., Satyanarayana, K., Rao, M.N.A., (1994) J. Clin. Biochem. Nutr, 17, p. 73; Satyanarayana, K., Deshpande, R.S., Subba Rao, B., Rao, M.N.A., (2002) Indian Drugs, 39, p. 578; Ammon, H.P.T., Wah, M.A., (1991) Plant Med, 57, p. 1; Kuttan, R., Banumathi, P., Nirmala, K., George, M.C., (1985) Cancer Letters, 29, p. 197; Sreejayan and Rao, M.N.A., J. Pharm. Pharmacol., 1994, 46, 1013; Anto, R.J., Sukumaran, K., Kuttan, G., Rao, M.N.A., Subbaraju, U., Kuttan, R., (1995) Cancer Letters, 97, p. 3; Boyd, A.P., (1989) Amm. Assoc. Cancer Res, 30, p. 652; Monk, A.P., Scudiero, P., Skehan, P., Shoemaker, K.D., Poull, D., Vistica, C., Hose, J.L., Vaigro, W., (1991) J. Natl. Cancer Inst, pp. 83-757; Weinstein, J.N., Myers, T.G.O., Connors, S.H., Friend, A.J., Fornance, Jr, Kohn, K.W., J.K:, Buolamwini, W.W., Zaharevitz, D.W., Bunow, R.E., and Pauli, K.D., Science, 1997, 343; Vilpo, J.A., Vilpo, L.M., Vourinen, P., Moilanen, E., MestaKetela, T., (1997) Anticancer Drug Design, 12, p. 75; Drapier, J.D., Hibbs, J.B., (1988) J .Immunol, 140, p. 2829; Hibbs, J.B., Taintor, R.R., Vavrin, Z., (1987) Science, Wash DC, 235, p. 473
PY - 2004
Y1 - 2004
N2 - Novel structural feature containing 4-[1-oxo-(substituted aryl)-2-propenyl]-3-phenylsydnones were synthesized and screened for anticancer activity. These compounds contain two pharmacophores,a,b unsaturated ketone moiety and sydnone nucleus. Three compounds were synthesized, and all of the three exhibited promising in vitro cytotoxicity in 56 cell lines representing cancers of non-small cell lung, colon, CNS, melanoma, ovarian, prostrate, breast and leukemia. Average growth inhibition of 50% was in the range of 1.7-3.5 μM. Methyl derivative was highly selective against SNB-75 tumor cell line of CNS. It was active at less than one nano mole. However, in vivo the activity was moderate by hollow fiber assay model.
AB - Novel structural feature containing 4-[1-oxo-(substituted aryl)-2-propenyl]-3-phenylsydnones were synthesized and screened for anticancer activity. These compounds contain two pharmacophores,a,b unsaturated ketone moiety and sydnone nucleus. Three compounds were synthesized, and all of the three exhibited promising in vitro cytotoxicity in 56 cell lines representing cancers of non-small cell lung, colon, CNS, melanoma, ovarian, prostrate, breast and leukemia. Average growth inhibition of 50% was in the range of 1.7-3.5 μM. Methyl derivative was highly selective against SNB-75 tumor cell line of CNS. It was active at less than one nano mole. However, in vivo the activity was moderate by hollow fiber assay model.
M3 - Article
SN - 0250-474X
VL - 66
SP - 679
EP - 683
JO - Indian Journal of Pharmaceutical Sciences
JF - Indian Journal of Pharmaceutical Sciences
IS - 5
ER -
SDG 3 Good Health and Well-being